OneMedNet Corporation (ONMDW) Stock Analysis

Company Overview

OneMedNet Corporation functions as a healthcare software provider dedicated to delivering digital medical image management, exchange, and sharing solutions across the Americas, Europe, and the Middle East. The company specifically offers iRWD, a platform designed to provide regulatory-grade imaging and clinical data tailored for the pharmaceutical and device manufacturing sectors. Although the company operates within the healthcare technology space, specific sector and industry classifications are not publicly disclosed in the available data. The firm employs 22 individuals to support its operations, while its market capitalization and annual revenue figures are not currently reported, which limits the ability to quantify its precise position relative to larger industry peers.

Financial Health

The company reported a trailing twelve-month revenue of $494,000, yet it recorded a net income loss of $-2,034,000 and an EBITDA of $-9,219,000. The substantial gap between the modest revenue figure and the significant net loss reveals a cost structure where expenses heavily outweigh earnings before interest, taxes, and amortization, suggesting high operating costs or one-time charges. Despite these losses, the company generated free cash flow of $4.86M, which indicates a degree of financial flexibility by showing that cash generation from operations exceeds capital expenditures and working capital changes. The balance sheet displays a price-to-book ratio of -0.86, while the firm holds $149,000 in cash against $388,000 in debt, resulting in a debt-to-equity ratio that is not applicable due to the negative equity position. The gross margin stands at -140.5%, the operating margin is -1262.7%, and the profit margin is 0.0%, all of which indicate that the company is currently operating at a loss on a per-revenue basis. Liquidity is constrained, as evidenced by a current ratio of 0.29, which signifies that current assets are less than one-third of current liabilities. Return on Equity is not applicable, while the return on assets is -197.3%, indicating that the company's assets are generating negative returns on the capital invested.

Valuation Assessment

Trailing P/E and forward P/E ratios are not applicable for OneMedNet Corporation due to the reported net losses, meaning these traditional metrics cannot be used to gauge expected earnings trajectories or valuation multiples. The price-to-book ratio of -0.86 indicates that the market is pricing the company at a significant discount relative to its book value, reflecting the negative equity and potential restructuring needs. Alternative valuation metrics such as price-to-sales and EV/EBITDA are also not available in the current dataset, which limits the comparative analysis against profitable peers. The stock trades with a 52-week high of $0.07 and a 52-week low of $0.05, and without a specific current price listed in the facts, the exact percentage deviation from this range cannot be calculated. The beta value is 1.09, which suggests that the stock's price volatility is slightly higher than the broader market, moving 9% more than the market index on average.

Growth & Income

Revenue growth year-over-year is reported at 24.6%, whereas earnings growth is not applicable due to the company's negative net income position. Since the company is not a dividend payer, there is no dividend yield or payout ratio to assess sustainability, and the firm is currently unable to distribute earnings to shareholders. The combination of positive revenue growth alongside negative earnings growth implies that the company is investing heavily in expansion or covering rising costs that have not yet translated into profitability. The overall growth and income profile reflects a pre-profitability stage where top-line expansion is occurring, but financial returns and shareholder distributions remain negative or non-existent.